Korro Bio, Inc. Impairment of Long-Lived Assets Held-for-use
Korro Bio, Inc. (KRRO) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2023-03-10
- Korro Bio, Inc. impairment of long-lived assets held-for-use for the quarter ending 2020-12-31 was $0.00.
- Korro Bio, Inc. impairment of long-lived assets held-for-use for the quarter ending 2020-09-30 was $0.00.
- Korro Bio, Inc. impairment of long-lived assets held-for-use for the quarter ending 2020-06-30 was $0.00.
- Korro Bio, Inc. impairment of long-lived assets held-for-use for the quarter ending 2020-03-31 was $0.00.
- Korro Bio, Inc. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
- Korro Bio, Inc. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
- Korro Bio, Inc. impairment of long-lived assets held-for-use for fiscal 2020 was $0.00.
- Korro Bio, Inc. impairment of long-lived assets held-for-use for fiscal 2019 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-10 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-10 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 derived: sum of 3 quarters · filed 2022-03-15 | $0.00 10-K · filed 2022-03-15 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-16 | $0.00 derived: sum of 2 quarters · filed 2020-11-16 | $0.00 10-Q · filed 2020-11-16 | $0.00 derived: sum of 4 quarters · filed 2021-03-29 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-12 | $0.00 10-Q · filed 2020-08-12 | $0.00 derived: sum of 3 quarters · filed 2021-03-29 | $0.00 derived: sum of 4 quarters · filed 2021-03-29 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-14 | $0.00 derived: sum of 2 quarters · filed 2021-03-29 | $0.00 derived: sum of 3 quarters · filed 2021-03-29 | $0.00 derived: sum of 4 quarters · filed 2021-03-29 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $0.00 derived: sum of 2 quarters · filed 2021-03-29 | $0.00 derived: sum of 3 quarters · filed 2021-03-29 | $0.00 10-K · filed 2021-03-29 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-16 | $0.00 derived: sum of 2 quarters · filed 2020-11-16 | $0.00 10-Q · filed 2020-11-16 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | $0.00 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-03-26 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |